Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study

Outcomes in classic Hodgkin lymphoma (cHL) have steadily improved; however, additional therapies are needed for patients who relapse or do not respond to novel agents. Here, we report the efficacy and safety of camidanlumab tesirine (Cami), an anti-CD25 antibody-drug conjugate, in patients with relapsed/refractory cHL after brentuximab vedotin/programmed cell death protein 1 inhibitor therapies from the phase 2 ADCT-301-201 study. Eligible patients were adults with cHL who had received ≥3 previous lines of systemic therapy (or ≥2 if ineligible for hematopoietic stem cell transplant). Patients received 45 μg/kg Cami (IV, once every 3 weeks) in cycles 1 to 2, followed by 30 μg/kg IV once every 3 weeks for ≤1 year. The primary end point was overall response rate (ORR) per 2014 Lugano classification. Secondary end points included complete response rate (CRR), progression-free survival (PFS), and overall survival (OS). In total, 117 patients were enrolled with a median age of 37.0 years (range, 19-87). The ORR was 70.1% (95% confidence interval [CI], 60.9-78.2), with a CRR of 33.3% (95% CI, 24.9-42.6). The median PFS was 9.13 months (95% CI, 5.3-15.0); median OS was not reached. Thirty-three (28.2%) patients discontinued treatment because of treatment-emergent adverse events; the most common reasons were skin and subcutaneous tissue disorders (n = 10 [8.5%] patients), infections and infestations (n = 5 [4.3%]), and nervous systems disorders (n = 5 [4.3%]). Guillain-Barré-type or polyradiculopathy-type events occurred in 8 (6.8%) patients. Cami was efficacious in this heavily pretreated population; however, the efficacy was overshadowed by substantial issues with the safety profile. This trial was registered at www.clinicaltrials.gov as #NCT04052997.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2025-08-14
DOI
https://doi.org/10.1182/bloodadvances.2024015600
Citations
3
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
4.41

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study

Luqiang Wang, Justin Paul Kline, Mehdi Hamadani, John Radford et al.
3 citations
Blood Advances
Lymphoma Diagnosis and Treatment
4.41
article

Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study

Luqiang Wang, Justin Paul Kline, Mehdi Hamadani, John Radford, Tatyana A. Feldman, Yanina Negievich, Paolo F. Caimi, Kerry J. Savage, Isabelle Bence‐Bruckler, Graham P. Collins, Kami J. Maddocks, Marie Toukam, Jens Wuerthner, Alex Francisco Herrera, Antonio Pinto, Mariana Bastos‐Oreiro, Brian T. Hess, Sunil Iyengar, Jerzy Dyczkowski, Carmelo Carlo‐Stella, Melanie Lucero, Stephen M. Ansell, Ranjana H. Advani, Olivier Casasnovas, Veronika Bachanová, Karin Havenith, William Townsend, Serafino Pantano, Nancy L. Bartlett, Pier Luigi Zinzani, Hans G. Cruz, Marc André, Árpád Szomor, Jiří Mayer
article en
3 citations

Abstract

Outcomes in classic Hodgkin lymphoma (cHL) have steadily improved; however, additional therapies are needed for patients who relapse or do not respond to novel agents. Here, we report the efficacy and safety of camidanlumab tesirine (Cami), an anti-CD25 antibody-drug conjugate, in patients with relapsed/refractory cHL after brentuximab vedotin/programmed cell death protein 1 inhibitor therapies from the phase 2 ADCT-301-201 study. Eligible patients were adults with cHL who had received ≥3 previous lines of systemic therapy (or ≥2 if ineligible for hematopoietic stem cell transplant). Patients received 45 μg/kg Cami (IV, once every 3 weeks) in cycles 1 to 2, followed by 30 μg/kg IV once every 3 weeks for ≤1 year. The primary end point was overall response rate (ORR) per 2014 Lugano classification. Secondary end points included complete response rate (CRR), progression-free survival (PFS), and overall survival (OS). In total, 117 patients were enrolled with a median age of 37.0 years (range, 19-87). The ORR was 70.1% (95% confidence interval [CI], 60.9-78.2), with a CRR of 33.3% (95% CI, 24.9-42.6). The median PFS was 9.13 months (95% CI, 5.3-15.0); median OS was not reached. Thirty-three (28.2%) patients discontinued treatment because of treatment-emergent adverse events; the most common reasons were skin and subcutaneous tissue disorders (n = 10 [8.5%] patients), infections and infestations (n = 5 [4.3%]), and nervous systems disorders (n = 5 [4.3%]). Guillain-Barré-type or polyradiculopathy-type events occurred in 8 (6.8%) patients. Cami was efficacious in this heavily pretreated population; however, the efficacy was overshadowed by substantial issues with the safety profile. This trial was registered at www.clinicaltrials.gov as #NCT04052997.

Blood AdvancesVol. 9(23)
Health Canada (CA), BC Cancer Agency (CA), University College Hospital (GB), City Of Hope National Medical Center (US), University of Minnesota (US), Cleveland Clinic (US), Hackensack University Medical Center (US), Mayo Clinic (US), Humanitas University (IT), University College London Hospitals NHS Foundation Trust (GB), Institute of Cancer Research (GB), Medical University of South Carolina (US), University of Ottawa (CA), Université de Bourgogne (FR), Providence College (US), Medical College of Wisconsin (US), Washington University in St. Louis (US), Masaryk University (CZ), Manchester Academic Health Science Centre (GB), University of Minnesota System (US), Ottawa Hospital (CA), Churchill Hospital (GB), Spinal Cord Injury BC (CA), WinnMed (US), University of Manchester (GB), Hospital General Universitario Gregorio Marañón (ES), University of Chicago (US), CHU Dinant Godinne UCL Namur (BE), University Hospital Brno (CZ), NBE Therapeutics (Switzerland) (CH), City of Hope (US), Adc Therapeutics (Switzerland) (CH), Istituto di Ematologia di Bologna (IT), e-Therapeutics (United Kingdom) (GB), Royal Marsden Hospital (GB), The Christie NHS Foundation Trust (GB), PTC Therapeutics (United States) (US), UCL Biomedical Research Centre (GB), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Maison des Sciences sociales et des Humanités de Dijon (FR), Oxford University Hospitals NHS Trust (GB), Hackensack Meridian Health (US), IRCCS Humanitas Research Hospital (IT), Ottawa Hospital Research Institute (CA), University College London (GB), The Ohio State University (US), University of Pecs (HU), University of Bologna (IT), Stanford University (US)
Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Spectrum Pharmaceuticals, Celgene, F. Hoffmann-La Roche, Regeneron Pharmaceuticals, BeiGene, Incyte, Omeros Corporation, Seagen, Astellas Pharma, University College London Hospitals NHS Foundation Trust, Swedish Orphan Biovitrum, Ipsen, EUSA Pharma, Genentech, Kite Pharma, Pharmacyclics, Daiichi Sankyo Europe
Good health and well-being
Openalex Percentile: Top 5%
Lymphoma Diagnosis and Treatment
4.41
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.